The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose Off time, total post dose On time and total post dose Good On time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose Off time, total post dose On time and total post dose Good On time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose Off time, total post dose On time and total post dose Good On time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose On time or Good On time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose Off time, total post dose On time and total post dose Good On time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating levodopa nave patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa nave patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.

Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose Off time, total post dose On time and total post dose Good On time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose Off time, total post dose On time and total post dose Good On time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Disclosed herein is a simple method for generation of high-throughput aerosols of monodisperse micro-shell particles. To create the aerosol, small nozzles are employed blowing slightly compressed air on a thin liquid film. This allows one to generate bubble aerosols including particles having a thin liquid shell surrounding a gas core, which are suspended in a carrier gas flow or environment. The diameter of the created liquid shells is uniform and scales with the inner diameter of the blowing nozzle, enabling control on the size of the produced monodispersed aerosol and formation of particles between few microns to several hundred of microns in outer diameter.